$PLX 09:10 AM EST, 11/27/2019 (MT Newswires) -- Protalix BioTherapeutics(PLX) , a biopharmaceutical company, said Wednesday it will provide an update on its drug candidate for the treatment of Fabry disease, PRX-102 (pegunigalsidase alfa), in New York on Dec. 2. The meeting will feature a presentation from David Warnock of the University of Alabama at Birmingham, who will discuss the current treatment landscape, as well as the unmet medical need for treating Fabry patients. The company's management team will also provide an update on PRX-102.
  • 2
  • 21